Mycobacterium bovis Bacillus Calmette-Guérin (BCG) is the most common intravesical immunotherapy used to fight early-stage bladder cancer.
U.S. providers and patients have been challenged in accessing BCG due to limitations in manufacturing capacity, resulting in worldwide shortages.
Premier’s Pharmacy team recently developed an overview document summarizing the therapeutic use of BCG and the current-state management approach given constraints.
Around BCG shortages, and overall in the Pharmacy space, the power of the Premier alliance connects people, data and knowledge to share intelligence, mitigation efforts and conservation strategies, and critical best practices with our members. Educational sessions, committees and other key forums provide visibility into what pharmacists and healthcare providers are facing, what’s working and what isn’t ─ and how we can tackle challenges together.
Premier will continue to share vital education, recommendations and best practices ─ and pursue crucial strategies to help our members get access to vital therapeutics.